Quarterly Result21 May 2026, 05:41 pm
Windlas Biotech FY26 Revenue Up 19% YoY to ₹904 Cr
AI Summary
Windlas Biotech Ltd reports strong FY26 results with revenue reaching ₹904 crores, a 19% YoY increase. CDMO revenue grew by 20% to ₹664 crores. Adjusted EBITDA rose by 26% to ₹121 crores, and adjusted PAT increased by 31% to ₹83 crores. EPS grew 8% YoY to ₹31.60. The company boasts a strong net liquidity of ₹251 crores and is net debt-free. Q4FY26 revenue stood at ₹238 crores, up 18% YoY, with adjusted EBITDA at ₹33 crores and adjusted PAT at ₹23 crores.
Key Highlights
- FY26 revenue reached ₹904 Cr, a 19% YoY growth.
- CDMO revenue for FY26 grew 20% YoY to ₹664 Cr.
- Adjusted EBITDA for FY26 increased 26% YoY to ₹121 Cr.
- Adjusted PAT for FY26 grew 31% YoY to ₹83 Cr.
- Company reports net liquidity of ₹251 Cr and is net debt-free.
Price Impact
More from WINDLAS*